These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1868246)

  • 1. Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts.
    Storb R; Sanders JE; Pepe M; Anasetti C; Appelbaum FR; Buckner CD; Deeg HJ; Doney K; Hansen J; Martin P
    Blood; 1991 Aug; 78(4):1144-5. PubMed ID: 1868246
    [No Abstract]   [Full Text] [Related]  

  • 2. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.
    Storb R; Deeg HJ; Farewell V; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J
    Blood; 1986 Jul; 68(1):119-25. PubMed ID: 3521761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
    Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942
    [No Abstract]   [Full Text] [Related]  

  • 4. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
    Storb R; Pepe M; Anasetti C; Appelbaum FR; Beatty P; Doney K; Martin P; Stewart P; Sullivan KM; Witherspoon R
    Blood; 1990 Sep; 76(5):1037-45. PubMed ID: 2203481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial.
    Storb R; Deeg HJ; Pepe M; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J
    Br J Haematol; 1989 Aug; 72(4):567-72. PubMed ID: 2673331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marrow transplant experience for children with severe aplastic anemia.
    Sanders JE; Storb R; Anasetti C; Deeg HJ; Doney K; Sullivan KM; Witherspoon RP; Hansen J
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia.
    Castro-Malaspina H; Childs B; Laver J; Shank B; Brochstein J; Gillio A; Flomenberg N; Young J; Boulad F; Black P
    Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):847-54. PubMed ID: 8040033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cyclophosphamide and total lymphoid irradiation combined with cyclosporine in bone marrow transplantation for transfused severe aplastic anemia.
    Miyamura K; Kojima S; Takeyama K; Matsushita T; Fukuda M; Horibe K; Minami S; Morishima Y; Matsuyama K; Kodera Y
    Bone Marrow Transplant; 1988 Sep; 3(5):457-61. PubMed ID: 3056553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy.
    Champlin RE; Ho WG; Nimer SD; Gajewski JG; Selch M; Burnison M; Holley G; Yam P; Petz L; Winston DJ
    Transplantation; 1990 Apr; 49(4):720-4. PubMed ID: 2326866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia.
    Storb R; Leisenring W; Deeg HJ; Anasetti C; Appelbaum F; Bensinger W; Buckner CD; Clift R; Doney K; Hansen J
    Blood; 1994 May; 83(9):2749-50. PubMed ID: 8167353
    [No Abstract]   [Full Text] [Related]  

  • 11. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome.
    Gluckman E; Horowitz MM; Champlin RE; Hows JM; Bacigalupo A; Biggs JC; Camitta BM; Gale RP; Gordon-Smith EC; Marmont AM
    Blood; 1992 Jan; 79(1):269-75. PubMed ID: 1728315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results.
    Horstmann M; Stockschläder M; Krüger W; Hoffknecht M; Betker R; Kabisch H; Zander A
    Ann Hematol; 1995 Aug; 71(2):77-81. PubMed ID: 7654856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.
    Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A
    Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease.
    Sorror ML; Leisenring W; Deeg HJ; Martin PJ; Storb R
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):567-8. PubMed ID: 15983557
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunologic recovery in human marrow graft recipients given cyclosporine or methotrexate for the prevention of graft-versus-host disease.
    Witherspoon RP; Deeg HJ; Lum LG; Ochs HD; Hansen JA; Thomas ED; Storb R
    Transplantation; 1984 May; 37(5):456-61. PubMed ID: 6233764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine as an alternative to cyclophosphamide in the treatment of chronic graft-versus-host disease.
    Bunjes D; Heit W; Arnold R; Schmeiser T; Heimpel H
    Transplantation; 1986 Feb; 41(2):170-2. PubMed ID: 3511579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine.
    Deeg HJ; Shulman HM; Schmidt E; Yee GC; Thomas ED; Storb R
    Transplantation; 1986 Nov; 42(5):497-501. PubMed ID: 3538535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marrow transplantation in aplastic anemia.
    Storb R; Buckner CD; Fefer A; Clift RA; Neiman PE; Gluksberg H; Lerner KG; Thomas ED
    Transplant Proc; 1974 Dec; 6(4):355-8. PubMed ID: 4612891
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bone marrow transplantation in pediatric patients: review of progress].
    Inoue S
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):994-1003. PubMed ID: 3551848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.